MasterControl preps for increasingly complex regulatory environment

By Melissa Fassbender contact

- Last updated on GMT

MasterControl's new headquarters in Salt Lake City, Utah. (Image: MasterControl)
MasterControl's new headquarters in Salt Lake City, Utah. (Image: MasterControl)

Related tags: Vice president, Pharmacology

MasterControl is expanding as pharma faces an increasingly complex regulatory environment, which has fueled “unprecedented growth,” says EVP.

The enterprise software solution provider renovated a six-floor 154,000 square-foot office building in Salt Lake City, Utah.

The new headquarters will house 300 employees, though the location was chosen with longevity in mind, according to the company – as it expects to double its workforce in the upcoming years.

MasterControl is seeing unprecedented growth in the demand for its solutions from the pharmaceutical and biotech industries​,” Matt Lowe, executive vice president of MasterControl told

As companies in the life sciences industry look for increased efficiencies in an increasingly complex global regulatory environment, MasterControl’s EQMS [Enterprise Quality Management Software] products are a natural fit​,” he said.

MasterControl enables companies to meet regulatory requirements and quality standards in multiple geographies by automating workflows and repurposing data and content to country-specific regulations, Lowe explained. 

Over the next five years, Lowe said the regulatory environment is expected to become more complex to navigate and will involve technology “in increasing doses​.”

This is manifest in many geographies even today with aspects of the regulatory process being mandated as electronic-only​,” he added. “If companies in the pharmaceutical space wish to remain competitive and get to market quickly, they will have to be prepared with the proper tools and processes​.”

Related topics: Markets & Regulations, Regulatory affairs

Related news

Related products

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more